Nutranomics to Launch Ready-to-Drink Product in Cosmoceutical and Anti-Aging Industry - NNRX Receives Expanded Purchase Order from Flantech Asia in Malaysia
15 Nov, 2013, 04:15 ET
DRAPER, Utah, Nov. 15, 2013 /PRNewswire/ -- Nutranomics, Inc. (OTCBB: NNRX) (OTCQB: NNRX) ("Nutranomics" or the "Company") announced today that the Company intends to launch several newly developed Nutranomics branded products in the emerging multi-billion dollar cosmoceutical and anti-aging industry.
The first Nutranomics branded product expected to be released from the potential new cosmoceutical and anti-aging line is the "Collagen Enhancer", a nutraceutical food supplement product designed to assist the body in the creation of collagen. Nutranomics anticipates launching the new 120ml ready-to-drink liquid formula in Asian and North American markets in January 2014. The ready-to-drink market is one of the fastest growing segments of the nutritional food supplement industry.
"The successful launch of this highly-anticipated new ready-to-drink product could open up many new opportunities within the anti-aging industry for Nutranomics," stated Nutranomics' CEO Dr. Tracy K. Gibbs. "As with all of our Nutranomics developed products, the Collagen Enhancer was tested under strict scientific protocols, and we believe that the Nutranomics Collagen Enhancer could dramatically impact the cosmoceutical and anti-aging industries as a standalone product and even more so as a potential key component in numerous other existing nutritional food products."
The Company is also pleased to report that it has received an expanded purchase order from Flantech Asia Sdn.Bhd ("Flantech Asia"), a Penang, Malaysia, based direct sales company with a primary focus on health and wellness related products. Founded in 2003, Flantech Asia is an active member of Direct Selling Association of Malaysia (DSAM).
"Flantech's long-term focus as a health and wellness products company has allowed us to build a strong relationship with them over the last ten years," stated Dr. Gibbs. "As a long-standing Nutranomics customer, I find it extremely encouraging that Flantech continues to support our product lineup in Malaysia and is enthusiastic to move forward with the addition of some of our newest products and to expand its current supplement offerings within the Asian marketplace."
Dr. Gibbs concluded, "Receiving purchase orders from established Nutranomics customers that include many of our newest products is a definite sign that our current Asian market expansion strategy is yielding some positive results. I anticipate that we will see many other current and future potential clients follow suit as our planned expansion efforts continue."
Nutranomics is a publicly traded company engaged in research and development of nutritional food products. In 1997, Nutranomics produced and branded its own product line, and began to sell to the retail outlets and to the public. Nutranomics has also produced formulas for hundreds of other companies. Nutranomics' mission is to increase human health and longevity through education and self-awareness. The Company has sales representatives throughout North America and Asia.
For further information regarding Nutranomics, Inc., please contact our investor relations representatives at [email protected] or call toll-free (888) 616-3999.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements." Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include the Company's planned Asian expansion plans, the receipt of additional purchase orders from Flantech or other current and/or future potential customers, the launch of Collagen Enhancer in January 2014, and the potential release of additional cosmoceutical products. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products and operating as a development stage company, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law, including the securities laws of the United States. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
SOURCE Nutranomics, Inc.
Share this article